Selective publication of antidepressant trials and its influence on apparent efficacy: Updated comparisons and meta-analyses of newer versus older trials
Published 2022 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Selective publication of antidepressant trials and its influence on apparent efficacy: Updated comparisons and meta-analyses of newer versus older trials
Authors
Keywords
Antidepressants, Metaanalysis, Depression, Drug therapy, Publication ethics, Randomized controlled trials, Drug interactions, Drug research and development
Journal
PLOS MEDICINE
Volume 19, Issue 1, Pages e1003886
Publisher
Public Library of Science (PLoS)
Online
2022-01-20
DOI
10.1371/journal.pmed.1003886
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Publication statuses of clinical trials supporting FDA-approved immune checkpoint inhibitors: a meta-epidemiological investigation
- (2019) Kenji Omae et al. BMC CANCER
- The cumulative effect of reporting and citation biases on the apparent efficacy of treatments: the case of depression
- (2018) Y. A. de Vries et al. PSYCHOLOGICAL MEDICINE
- Registration, results reporting, and publication bias of clinical trials supporting FDA approval of neuropsychiatric drugs before and after FDAAA: a retrospective cohort study
- (2018) Constance X. Zou et al. Trials
- Association of the FDA Amendment Act with trial registration, publication, and outcome reporting
- (2017) Adam T. Phillips et al. Trials
- Measuring clinical trial transparency: an empirical analysis of newly approved drugs and large pharmaceutical companies
- (2017) Jennifer E Miller et al. BMJ Open
- Analysis of the Effect of Desvenlafaxine on Anxiety Symptoms Associated with Major Depressive Disorder: Pooled Data from 9 Short-Term, Double-blind, Placebo-Controlled Trials
- (2017) Karen A. Tourian et al. CNS SPECTRUMS
- Bias in the reporting of harms in clinical trials of second-generation antidepressants for depression and anxiety: A meta-analysis
- (2016) Ymkje Anna de Vries et al. EUROPEAN NEUROPSYCHOPHARMACOLOGY
- Protocol registration and selective outcome reporting in recent psychiatry trials: new antidepressants and cognitive behavioural therapies
- (2015) K. Shinohara et al. ACTA PSYCHIATRICA SCANDINAVICA
- Vilazodone: A Review in Major Depressive Disorder in Adults
- (2015) Paul L. McCormack DRUGS
- A Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of 2 Doses of Vortioxetine in Adults With Major Depressive Disorder
- (2015) Atul R. Mahableshwarkar et al. JOURNAL OF CLINICAL PSYCHIATRY
- A Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Vortioxetine 10 mg and 20 mg in Adults With Major Depressive Disorder
- (2015) Paula L. Jacobsen et al. JOURNAL OF CLINICAL PSYCHIATRY
- Desvenlafaxine for the Acute Treatment of Depression: A Systematic Review and Meta-analysis
- (2015) Z. Laoutidis et al. PHARMACOPSYCHIATRY
- A randomized, double-blind, duloxetine-referenced study comparing efficacy and tolerability of 2 fixed doses of vortioxetine in the acute treatment of adults with MDD
- (2015) Atul R. Mahableshwarkar et al. PSYCHOPHARMACOLOGY
- Clinical trial registration, reporting, publication and FDAAA compliance: a cross-sectional analysis and ranking of new drugs approved by the FDA in 2012
- (2015) Jennifer E Miller et al. BMJ Open
- Reporting Bias in Clinical Trials Investigating the Efficacy of Second-Generation Antidepressants in the Treatment of Anxiety Disorders
- (2015) Annelieke M. Roest et al. JAMA Psychiatry
- A Placebo-Controlled Study Evaluating the Efficacy and Safety of Flexible-Dose Desvenlafaxine Treatment in Outpatients with Major Depressive Disorder
- (2015) Alan D. Feiger et al. CNS SPECTRUMS
- Desvenlafaxine for the treatment of major depressive disorder
- (2014) Susan G Kornstein et al. EXPERT OPINION ON PHARMACOTHERAPY
- Levomilnacipran ER 40 mg and 80 mg in patients with major depressive disorder: a phase III, randomized, double-blind, fixed-dose, placebo-controlled study
- (2014) David Bakish et al. JOURNAL OF PSYCHIATRY & NEUROSCIENCE
- Publication Bias, with a Focus on Psychiatry: Causes and Solutions
- (2013) Erick H. Turner CNS DRUGS
- Efficacy and safety of vortioxetine (Lu AA21004), 15 and 20 mg/day
- (2013) Jean-Philippe Boulenger et al. INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY
- Efficacy and Safety of Levomilnacipran Sustained Release in Moderate to Severe Major Depressive Disorder
- (2013) Stuart A. Montgomery et al. JOURNAL OF CLINICAL PSYCHIATRY
- Efficacy and Safety of Levomilnacipran Sustained Release 40 mg, 80 mg, or 120 mg in Major Depressive Disorder
- (2013) Gregory M. Asnis et al. JOURNAL OF CLINICAL PSYCHIATRY
- A Phase III, Double-Blind, Placebo-Controlled, Flexible-Dose Study of Levomilnacipran Extended-Release in Patients With Major Depressive Disorder
- (2013) Angelo Sambunaris et al. JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY
- How to access and process FDA drug approval packages for use in research
- (2013) E. H. Turner BMJ-British Medical Journal
- A randomized, double-blind trial of 2.5 mg and 5 mg vortioxetine (Lu AA21004) versus placebo for 8 weeks in adults with major depressive disorder
- (2012) Atul R. Mahableshwarkar et al. CURRENT MEDICAL RESEARCH AND OPINION
- Vilazodone for major depressive disorder: a systematic review of the efficacy and safety profile for this newly approved antidepressant - what is the number needed to treat, number needed to harm and likelihood to be helped or harmed?
- (2012) L. Citrome INTERNATIONAL JOURNAL OF CLINICAL PRACTICE
- A randomized, double-blind, placebo-controlled 6-wk trial of the efficacy and tolerability of 5 mg vortioxetine in adults with major depressive disorder
- (2012) Rakesh Jain et al. INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY
- The Evolution of Trial Registries and Their Use to Assess the Clinical Trial Enterprise
- (2012) Kay Dickersin JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- A Randomized, Double-Blind, Placebo-Controlled 8-Week Trial of the Efficacy and Tolerability of Multiple Doses of Lu AA21004 in Adults With Major Depressive Disorder
- (2012) Neven Henigsberg et al. JOURNAL OF CLINICAL PSYCHIATRY
- Implementation of a publication strategy in the context of reporting biases. A case study based on new documents from Neurontin® litigation
- (2012) S Swaroop Vedula et al. Trials
- Publication Bias in Antipsychotic Trials: An Analysis of Efficacy Comparing the Published Literature to the US Food and Drug Administration Database
- (2012) Erick H. Turner et al. PLOS MEDICINE
- A randomised, double-blind, placebo controlled, duloxetine-referenced, fixed-dose study of three dosages of Lu AA21004 in acute treatment of major depressive disorder (MDD)
- (2011) David S. Baldwin et al. EUROPEAN NEUROPSYCHOPHARMACOLOGY
- A double-blind, randomized, placebo-controlled, active reference study of Lu AA21004 in patients with major depressive disorder
- (2011) Enric Alvarez et al. INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY
- A Randomized, Double-Blind, Placebo-Controlled, 8-Week Study of Vilazodone, a Serotonergic Agent for the Treatment of Major Depressive Disorder
- (2011) Arif Khan et al. JOURNAL OF CLINICAL PSYCHIATRY
- The ClinicalTrials.gov Results Database — Update and Key Issues
- (2011) Deborah A. Zarin et al. NEW ENGLAND JOURNAL OF MEDICINE
- Negative results are disappearing from most disciplines and countries
- (2011) Daniele Fanelli SCIENTOMETRICS
- Reporting bias in medical research - a narrative review
- (2010) Natalie McGauran et al. Trials
- Efficacy, safety, and tolerability of fixed-dose desvenlafaxine 50 and 100 mg/day for major depressive disorder in a placebo-controlled trial
- (2009) Patrice Boyer et al. INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY
- Evidence for Efficacy and Tolerability of Vilazodone in the Treatment of Major Depressive Disorder
- (2009) Karl Rickels et al. JOURNAL OF CLINICAL PSYCHIATRY
- Efficacy, safety, and tolerability of desvenlafaxine 50 mg/day and 100 mg/day in outpatients with major depressive disorder
- (2008) Michael R. Liebowitz et al. CURRENT MEDICAL RESEARCH AND OPINION
- A pooled analysis of two placebo-controlled trials of desvenlafaxine in major depressive disorder
- (2008) Daniel Z. Lieberman et al. INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY
- Selective Publication of Antidepressant Trials and Its Influence on Apparent Efficacy
- (2008) Erick H. Turner et al. NEW ENGLAND JOURNAL OF MEDICINE
- Systematic Review of the Empirical Evidence of Study Publication Bias and Outcome Reporting Bias
- (2008) Kerry Dwan et al. PLoS One
- MEDICINE: Moving Toward Transparency of Clinical Trials
- (2008) D. A. Zarin et al. SCIENCE
- Reporting Bias in Drug Trials Submitted to the Food and Drug Administration: Review of Publication and Presentation
- (2008) Kristin Rising et al. PLOS MEDICINE
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started